leisure time -WSS

leisure time

author：explore 2025-08-24 04:08:18 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Vivek Ramaswamy made waves in the debate, much as in biotech

focus

WSS

Meadows told special counsel he could not recall Trump ever declassifying Mar

Hospital at home shows how to bring innovation to health care

California store owner shot dead in dispute over displaying Pride flag: Police

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Crowdfunding for unproven stem cell procedures spreads misinformation

As obesity drug market grows, telehealth companies court payers

focus

leisure time

hotspot

Drug repurposing or repositioning? The language matters

FDA greenlights medical device to combat bladder issues

Moonlake's readout produced a cash windfall. Risks remain

Can U.S. cancer drug shortages be fixed?

Jerome Adams on the need for new antivirals for Covid

Former Pear Therapeutics executives start new VC firm

Medicare details structure of new drug price negotiation program

Lupron, used to halt puberty in children, may cause lasting health problems

Medical records are filled with copy

Health officials lay out plans to cope with respiratory virus season

knowledge

'Screen and refer' systems are hurting patients

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Fatty liver disease was alleviated by Lilly’s ‘triple

Roche's accidental data boosts hopes for anti

Kellogg’s is going to war over Mexico’s nutrition label rules

Crowdfunding for unproven stem cell procedures spreads misinformation

focus

entertainment

hotspot

focus